Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 5, 2010, Pages 1311-1319

  Shitara, Kohei ^a   Muro, Kei ^a   Ito, Seiji ^a   Sawaki, Akira ^a   Tajika, Masahiro ^a   Kawai, Hiroki ^a   Yokota, Tomoya ^a   Takahari, Daisuke ^a   Shibata, Takashi ^a   Ura, Takashi ^a   Ito, Hidemi ^a   Hosono, Satoyo ^a   Kawase, Takakazu ^a   Watanabe, Miki ^a   Tajima, Kazuo ^a   Yatabe, Yasushi ^a   Tanaka, Hideo ^a,b   Matsuo, Keitaro ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLIC ACID; IRINOTECAN; METHOTREXATE; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; COMBINATION CHEMOTHERAPY; DIETARY INTAKE; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; GENE FREQUENCY; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FOLIC ACID; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 77952028996     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1257     Document Type: Article

References (34)

1. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
2. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673
3. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-1069
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338 (Pubitemid 37328853)
5. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009;45:1333-1351
6. Lee J, Jeong CK, Hong SP, et al. Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer. Korean J Gastroenterol 2005;46:32-38
7. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006;24:1883-1889 (Pubitemid 46638987)
8. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF. Polymorphism in the 3-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine based chemotherapy. J Hum Genet 2006;51:155-160
9. Keam B, Im SA, Han SW, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148. (Pubitemid 351998114)
10. Lu JW, Gao CM, Wu JZ, Sun XF, Wang L, Feng JF. Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Ai Zheng 2004;23:958-962
11. Branda RF, Nigels E, Lafayette AR, Hacker M. Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 1998;92:2471-2476 (Pubitemid 28452990)
12. Branda RF, Chen Z, Brooks EM, Naud SJ, Trainer TD, McCormack JJ. Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med 2002;140:358-368 (Pubitemid 35302029)
13. Ho C, Ng K, O'Reilly S, Gill S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a populationbased analysis. Clin Colorectal Cancer 2005;5:279-282
14. Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. Phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006;94:964-968
15. Lin D, Li H, Tan W, Miao X, Wang L. Genetic polymorphisms in folatemetabolizing enzymes and risk of gastroesophageal cancers: a potential nutrient-gene interaction in cancer development. Forum Nutr 2007;60:140-145
16. Tan W, Miao X, Wang L, et al. Significant increase in risk of gastroesophageal cancer is associated with interaction between promoter polymorphisms in thymidylate synthase and serum folate status. Carcinogenesis 2005;26:1430-1435 (Pubitemid 41417886)
17. Galván-Portillo MV, Cantoral A, Oñate-Ocaña LF, et al. Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT carriers. Eur J Nutr 2009;48:269-276
18. Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A model of practical cancer prevention for out-patients visiting a hospital: the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev 2000;1:35-47.
19. Hamajima N, Matsuo K, Saito T, et al. Gene-environment interactions and polymorphism studies of cancer risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACCII). Asian Pac J Cancer Prev 2001;2:99-107. (Pubitemid 32706681)
20. Tokudome Y, Goto C, Imaeda N, et al. Relative validity of a short food frequency questionnaire for assessing nutrient intake versus three-day weighed diet records in middle-aged Japanese. J Epidemiol 2005;15:135-145 (Pubitemid 41403851)
21. Imaeda N, Goto C, Tokudome Y, Hirose K, Tajima K, Tokudome S. Reproducibility of a short food frequency questionnaire for Japanese general population. J Epidemiol 2007;17:100-107
22. Imaeda N, Goto C, Tokudome Y, Hirose K, Tajima K, Tokudome S. Dietary supplement use by community-living population in Japan: data from the National Institute for Longevity Sciences Longitudinal Study of Aging (NILS-LSA). J Epidemiol 2006;16:249-260
23. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986;124:17-27. (Pubitemid 16095831)
24. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221
25. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402-3407 (Pubitemid 43917349)
26. Imamura H, Iishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer(GC0301/TOP-002). 2008 Gastrointestinal Cancer Symposium; Abstract #5, Orland, USA. 2008.
27. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59
28. Yamao T, Shimada Y, Shirao K, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004;34:316-322 (Pubitemid 43118050)
29. Lutz MP, Wilke H, Wagener DJ, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HDFU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007;25:2580-2585 (Pubitemid 47044813)
30. Kawakami K, Watanabe G. The association of thymidylate synthase mRNA expression with its three gene polymorphisms in colorectal cancer. Proc Am Assoc Cancer Res 2004;45:2104.
31. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;15:319-327 (Pubitemid 38638919)
32. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001;19:383-386
33. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
34. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002;17:46-49 (Pubitemid 41398991)